CollPlant Biotechnologies (CLGN) to Release Earnings on Wednesday

CollPlant Biotechnologies (NASDAQ:CLGN) is expected to release its Q2 2025 earnings data before the market opens on Wednesday, August 20th. Analysts expect CollPlant Biotechnologies to post earnings of $0.29 per share and revenue of $8.91 million for the quarter.

CollPlant Biotechnologies (NASDAQ:CLGN) last released its earnings results on Wednesday, June 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.24. CollPlant Biotechnologies had a negative net margin of 560.92% and a negative return on equity of 87.33%. The company had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $9.76 million. On average, analysts expect CollPlant Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CollPlant Biotechnologies Trading Up 5.7%

NASDAQ CLGN opened at $3.15 on Wednesday. CollPlant Biotechnologies has a 12 month low of $1.31 and a 12 month high of $5.45. The stock has a market cap of $40.07 million, a price-to-earnings ratio of -2.58 and a beta of 1.47. The company’s 50 day moving average is $1.90 and its two-hundred day moving average is $2.49.

Wall Street Analyst Weigh In

Separately, D. Boral Capital decreased their target price on shares of CollPlant Biotechnologies from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Wednesday, May 28th.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.